Combining STING & TLR9 pathway agonists:

"The aim of this study was to develop a highly immunogenic vaccine using pattern recognition receptor agonists in combination with synthetic long peptides to induce potent neoantigen-specific T cell responses. We determined that the combination of the TLR9 agonist K-type CpG oligodeoxynucleotides (K3 CpG) with the STING agonist c-di-AMP (K3/c-di-AMP combination) significantly increased dendritic cell activation."
#Immunology #Immunotherapy #Vaccines

https://journals.aai.org/jimmunol/article/doi/10.4049/jimmunol.2300038/266500/TLR9-plus-STING-Agonist-Adjuvant-Combination